Tumor Necrosis Factor news

All news on Tumor Necrosis Factor (also known as TNF, Cachectin, TNF-α, TNF-alpha, and TNFSF2): plants, production capacities, investments and involved companies.

20 April 2026

Asahi Kasei launches Phase I trial of AK1940 for autoimmune diseases

Peptide-based TNFR1 antagonist discovered with PeptiDream showed activity in animal models; Japan trial began Apr 19 to evaluate PK, safety and tolerability of subcutaneous doses in healthy volunteers
6 October 2025

Merck Launches Phase 2b Trials for Tulisokibart in Three Inflammatory Diseases

Merck starts Phase 2b trials for tulisokibart in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis, targeting over 640 patients globally.

Who will be producing Tumor Necrosis Factor in the future?

Find out with chemXplore Alpha

Learn more